SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNAP
SNAP 7.800+2.6%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (82)11/24/1999 7:56:00 AM
From: Mike McFarland   of 124
 
On page 12 of the SNAP '98 Annual
Y2 is listed as having primary indication
for Pain...Status is at the 'Discovery'
stage, and there is a footnote While
Synpatic is currently conducting this
program independently, Synaptic has agreed
to reserve the Y2 receptor as a potential
target for drugs for the alleviation of
pain exclusively for its collaboration
with Grunenthal."

NPY5, Obesity, Early Preclinical, Novartis.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News